| |
N (%) of patients
|
N (IR) of deaths
|
HR (95% CI)a
|
|---|
|
By sites of first malignancy
|
|
Colon and Rectum
|
6463 (17.8)
|
681 (2.1)
|
0.95 (0.88–1.03)
|
|
Uterine corpus
|
6057 (16.7)
|
610 (1.8)
|
0.98 (0.90–1.06)
|
|
Blood
|
3887 (10.7)
|
407 (2.3)
|
1.16 (1.05–1.28)
|
|
Skin
|
3489 (9.6)
|
309 (1.6)
|
0.96 (0.86–1.07)
|
|
Lung and Bronchus
|
3092 (8.5)
|
418 (4.1)
|
1.85 (1.68–2.03)
|
|
Thyroid
|
2722 (7.5)
|
207 (1.4)
|
0.93 (0.81–1.07)
|
|
Ovary
|
1612 (4.4)
|
181 (2.3)
|
1.19 (1.02–1.37)
|
|
Urinary Bladder
|
1547 (4.3)
|
177 (2.2)
|
1.22 (1.05–1.42)
|
|
Kidney
|
1382 (3.8)
|
116 (1.9)
|
1.01 (0.84–1.21)
|
|
Uterine cervix
|
1123 (3.1)
|
132 (2.0)
|
1.01 (0.85–1.20)
|
|
Others
|
4939 (13.6)
|
591 (2.9)
|
1.35 (1.25–1.47)
|
|
By tumor stage of first malignancy b
|
|
Localized
|
20,100 (62.3)
|
1906 (1.8)
|
0.98 (0.94–1.03)
|
|
Regional
|
7088 (22.0)
|
802 (2.4)
|
1.20 (1.12–1.29)
|
|
Distant
|
2661 (8.3)
|
379 (4.7)
|
1.63 (1.47–1.80)
|
|
Unstaged
|
2394 (7.4)
|
335 (3.3)
|
1.36 (1.22–1.51)
|
|
By chemotherapy and radiotherapy for first malignancy
|
|
No/unknown
|
24,129 (66.4)
|
2580 (2.1)
|
1.09 (1.05–1.13)
|
|
Radiotherapy only
|
4816 (13.3)
|
470 (2.3)
|
1.12 (1.03–1.23)
|
|
Chemotherapy only
|
4796 (13.2)
|
505 (2.0)
|
1.12 (1.02–1.22)
|
|
Chemotherapy plus radiotherapy
|
2572 (7.1)
|
274 (2.9)
|
1.44 (1.28–1.63)
|
- Abbreviations: CI Confidence interval, HR Hazards ratio, IR Mortality rate per 100 person-years, N Number of deaths
- a HR was adjusted for age (continuous) and calendar period at diagnosis, race, cohabitation status, percentile of cost of living and high-school education in county of residence, tumor stage, histology, tumor grade, estrogen receptor status, progesterone receptor status, and human epidermal growth factor receptor 2 status, surgery, radiotherapy, and chemotherapy
- b BCa-2 patients with blood malignancy as first malignancy were removed from this analysis
